(IN BRIEF) Researchers from LMU have discovered that CD8-positive T cells, a type of immune cell, play a crucial role in the early stages of multiple sclerosis (MS). By studying identical twins, where one twin has MS and the other … Read the full press release
Posted in Business, Education, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Science, Technology
Tagged CD8-positive T cells, Diagnosing, Immune System Signals, LMU Munich, multiple sclerosis, Preventing, wellbeing
(IN BRIEF) Sanofi’s phase 3 study for its drug tolebrutinib has shown promising results in treating non-relapsing secondary progressive multiple sclerosis (nrSPMS), a condition with no current approved therapies. The HERCULES study revealed that tolebrutinib successfully delayed disability progression in … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged activated microglia, annualized relapse rate (ARR), B lymphocytes, brain-penetrant BTK inhibitor, central nervous system (CNS), confirmed disability progression (CDP), Copenhagen, Denmark, disability accumulation, European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), GEMINI 1 and 2 phase 3 studies, HERCULES phase 3 study, Houman Ashrafian, innate immunity, multiple sclerosis, neuroinflammation, non-relapsing secondary progressive MS (nrSPMS), PERSEUS phase 3 study, primary progressive MS, Sanofi, teriflunomide, tolebrutinib
(IN BRIEF) Sanofi’s experimental CD40L antibody, frexalimab, demonstrates encouraging results in a 48-week phase 2 study for relapsing multiple sclerosis (MS). Presented at the American Academy of Neurology Annual Meeting, the data reveals sustained reduction in disease activity and favorable … Read the full press release
Posted in Business, Education, Financial, France, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged CD40L antibody, Erik Wallström, Frexalimab, multiple sclerosis, Patrick Vermersch, safety, Sanofi
(IN BRIEF) Roche, a leading healthcare company, has announced that its Elecsys Neurofilament Light Chain (NfL) test for Multiple Sclerosis (MS) has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). The Elecsys NfL test is designed … Read the full press release
Posted in Business, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged Elecsys NfL Test, FDA, Matt Sause, multiple sclerosis, Roche
(IN BRIEF) Alexion, a subsidiary of AstraZeneca Rare Disease, is set to present new data at the 9th Joint Meeting of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple … Read the full press release
Posted in Business, Education, Healthcare, Industrial, Management, Media, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Alexion, Alize Vives, Anna Francis, AQP4, AstraZeneca, Christophe Hotermans, ECTRIMS-ACTRIMS Meeting, effectiveness, Jin Nakahara, Justin Lee, Michael Levy, multiple sclerosis, NMOSD, Rare Neurological Disorder, rituximab, Sami Fam, Soliris, treatment, Ultomiris, Viktoria Papp
(IN BRIEF) Roche has announced positive late-breaking data from the Phase III OCARINA II study, which demonstrates the effectiveness of OCREVUS as a twice-yearly, 10-minute subcutaneous injection for patients with relapsing or primary progressive multiple sclerosis (RMS or PPMS). The … Read the full press release
(IN BRIEF) Merck has presented new data on evobrutinib, an investigational BTK inhibitor, at the 9th Joint ECTRIMS-ACTRIMS congress. The data from an ongoing Phase II open-label extension study of evobrutinib in patients with relapsing multiple sclerosis (RMS) show sustained … Read the full press release
Posted in Business, Education, Germany, Healthcare, Industrial, Management, News, Pharma & Biotech, Science
Tagged BTKi, Evobrutinib, Jan Klatt, Merck, multiple sclerosis, relapsing multiple sclerosis (RMS), treatment
(IN BRIEF) Merck, a prominent science and technology company, has revealed new findings from the MAVENCLAD® (cladribine tablets) MAGNIFY-MS study at the 9th Joint ECTRIMS-ACTRIMS meeting in Milan. The study demonstrated that patients with relapsing multiple sclerosis (RMS) experienced a … Read the full press release
Posted in Business, Germany, Healthcare, Industrial, Management, News, Pharma & Biotech, Science
Tagged Alexander Kulla, MAVENCLAD, Merck, multiple sclerosis, Neuronal Injury, reduction
(IN BRIEF) H.U. Group Holdings Inc. and Fujirebio have announced the launch of Lumipulse G NfL CSF and Lumipulse G NfL Blood assays for the fully automated random-access LUMIPULSE G immunoassay systems. These assays can quantitatively measure Neurofilament light (NfL) … Read the full press release
Posted in Belgium, Education, Healthcare, Management, News, Science, Technology
Tagged Alzheimer’s disease, Belgium, Christiaan De Wilde, CLEIA, Fujirebio, H.U. Group Holdings, human cerebrospinal fluid (CSF), LUMIPULSE G immunoassay systems, Lumipulse G NfL Blood assays, Lumipulse G NfL CSF, multiple sclerosis, Neurofilament light (NfL), Parkinson disease, plasma/serum, Quantitative NfL Assays, Research Use Only
(PRESS RELEASE) ENSCHEDE, Netherlands, 28-Feb-2022 — /EuropaWire/ — University of Twente, a Enschede, NL based public technical university, has announced that its associate professor Kerensa Broersen has been granted Vici funding from NWO, the Dutch Research Council. Kerensa Broersen, associate … Read the full press release
Posted in Education, Financial, Healthcare, Netherlands, Science, Technology
Tagged autism spectrum disorders, Brain, brain function, brain tumours, brain-related disorders, intestinal bacteria, Kerensa Broersen, multiple sclerosis, neurodegeneration, NWO, Parkinson's disease, schizophrenia, Stem cells, TTW, Veni, Vici funding, Vici grant, Vidi grants, ZonMw
Further strengthens core R&D areas of autoimmune and allergic diseases Provides full control of brain-penetrant BTK inhibitor SAR442168 in multiple sclerosis (MS), making commercialization more efficient and eliminating future royalty payments Allows expansion of SAR442168 development program into other central … Read the full press release
Posted in Business, France, Healthcare, Investment, News, Pharma & Biotech
Tagged acquisition, allergic diseases, Arnaud Delepine, Ashleigh Koss, autoimmune diseases, biopharmaceutical, BofA Securities, Bruton tyrosine kinase, BTK inhibitor, BTK inhibitor ‘168, Centerview Partners LLC, Christopher Chai, commercialization, Cooley LLP, Eva Schaefer-Jansen, Evercore, Fara Berkowitz, Felix Lauscher, Gotshal & Manges LLP, John Reed M.D. Ph.D., Martin Babler, MS, multiple sclerosis, Nicolas Kressmann, pathophysiology, Paul Hudson, Paul Laland, Pharmaceutical, Principia, Principia Biopharma, PRN473 Topical, rilzabrutinib, Sanofi, SAR442168, Suzanne Greco, Weil, Yvonne Naughton
GENEVA, 16-May-2018 — /EuropaWire/ — Multiple sclerosis, which affects 1 in 1,000 people, is frequently characterised by relapses associated with variable functional impairments including among others vision problems, impairment of locomotor functions or difficulties with speech. There is still no cure … Read the full press release
Participation in private placement as a cornerstone investor EBRD participates in US$ 51m equivalent private placement of Mabion Mabion is leading biotechnology company in Poland EBRD to invest US$ 18 million (PLN 61.4 million) LONDON, 26-Mar-2018 — /EuropaWire/ — The EBRD … Read the full press release
Posted in Banks, Chemicals, Financial, Investment, Poland, Science, Technology, United Kingdom
Tagged Biosimilar, biotechnology, EBRD, investment, Mabion S.A., multiple sclerosis, Private Placement, rituximab
Medicine to be voluntarily withdrawn from the market by the company LONDON, 06-Mar-2018 — /EuropaWire/ — The European Medicines Agency (EMA) has started an urgent review of the multiple sclerosis medicine Zinbryta (daclizumab) following 7 cases of serious inflammatory brain disorders … Read the full press release
Novartis and Pear Therapeutics to collaborate on prescription software applications aimed to treat patients with schizophrenia and multiple sclerosis Collaboration combines Novartis’ leadership in biomedical research and clinical development with Pear’s expertise in digital therapeutics Novartis continues to embrace emerging … Read the full press release
MUNICH, 09-Jan-2018 — /EuropaWire/ — Multiple Sclerosis (MS) is a chronic inflammatory disease of the central nervous system, in which the body’s own immune cells attack the fatty, insulating myelin sheath surrounding nerve fibers. The regeneration of intact myelin … Read the full press release
Preliminary research indicates most MS carers are between the ages of 18-34, the prime of their lives Largest global MS carer survey with International Alliance of Carer Organizations (IACO) to help identify unmet needs and social impact Darmstadt, Germany, 31-May-2017 … Read the full press release
Posted in Germany, Healthcare
Tagged Ali-Frédéric BenAmor, care partner survey, IACO, M&S, Merck, multiple sclerosis, Peer Baneke, Rick Greene, World MS Day 2017
Subgroup analysis shows >80% reduction in the risk of disability progression with Cladribine Tablets vs placebo DARMSTADT, 02-May-2017 — /EuropaWire/ — Merck, a leading science and technology company, announced the presentation of new analyses of efficacy and safety data for … Read the full press release
A large global new partnership called ‘MultipleMS’, coordinated by Karolinska Institute in Sweden, has been awarded 15 million euro from the European Commission in the Horizon2020 program to find novel and better treatments for Multiple Sclerosis (MS). In this project, … Read the full press release
On 9 September, Proximus received the MS@Work 2015 Award. The Award was presented by the National Belgian Multiple Sclerosis League as recognition for the positive policy Proximus pursues with regard to employing people with Multiple Sclerosis (MS). BRUSSELS, 14-9-2015 — … Read the full press release
Posted in Awards, Belgium, Healthcare, Non Profit, Society
Tagged MS@Work 2015 Award, multiple sclerosis, National Belgian Multiple Sclerosis League, Proximus
Novartis strengthens multiple sclerosis focus with the addition of Ofatumumab to leading MS portfolio which includes Gilenya and investigational treatments BAF312 and CJM112 Ofatumumab is a fully human monoclonal antibody for relapsing remitting multiple sclerosis (RRMS) which targets CD20 and … Read the full press release
Posted in Healthcare, Investment, Pharma & Biotech, Switzerland
Tagged Gilenya®, GlaxoSmithKline plc (GSK), multiple sclerosis, Novartis, Ofatumumab
The new RebiSmart® injection device offers many new updates including wireless transmission of injection times and doses MSdialog™software is designed to more effectively engage people with MS and their health care providers with treatment adherence information and health related outcome reports … Read the full press release
Posted in Germany, Healthcare, Internet & Online, Pharma & Biotech, Technology
Tagged M&S, Merck Serono, MSdialog, multiple sclerosis, RebiSmart
16-8-2013 — /EuropaWire/ — Immunologists at LMU have come up with a new technique that can be used both to fight tumors and to treat autoimmune diseases. A new grant from the Federal Ministry for Education and Research will enable the … Read the full press release
Posted in Education, Germany, Healthcare, Pharma & Biotech, Science
Tagged autoimmune disease, autoimmune diseases, BMBF, Clinical Neuroimmunology, Cytotoxic T cells, fight tumors, LMU, multiple sclerosis, pathogen-derived protein fragments, peptides, Privatdozent Dr. Klaus Dornmair, Prof. Jörg Prinz, psoriasis, T cells, treat autoimmune diseases, tumor-specific antigens, tumors, Validation of the Innovation Potential of Scientific Research
Princeton, New Jersey, 29-7-2013 — /EuropaWire/ — Sandoz announced today that the US Federal Circuit Court of Appeals has invalidated several patents asserted against the company by Teva Pharmaceuticals in litigation concerning a generic version of Copaxone® – one of the leading … Read the full press release
Cordoba, Spain, 12-6-2013 — /europawire.eu/ — VivaCell Biotechnology España S.L., Cordoba, Spain today announced that it has entered into joint Research Collaboration and Commercialization Agreements with Aphios Corporation, USA, to develop therapeutics for multiple sclerosis and other neurodegenerative diseases of the central … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Spain
Tagged Aphios Corporation, biotech company, biotech development, biotech pharma companies, biotechnology, cannabinoid receptor, cannabinoids, central nervous system, CNS and neurological disorders, Cordoba, endocannabinoid system, multiple sclerosis, neurodegenerative diseases, novel class of compounds, therapeutics for multiple sclerosis, VivaCell Biotechnology, VivaCell Biotechnology España S.L.
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
